Exploring the Mechanism of Salvianolic Acid B against Myocardial Ischemia-Reperfusion Injury Based on Network Pharmacology

Qianping Mao,Chongyu Shao,Huifen Zhou,Li Yu,Yida Bao,Yali Zhao,Jiehong Yang,Haitong Wan

DOI: https://doi.org/10.3390/ph17030309

IF: 4.6

2024-02-29

Pharmaceuticals

Abstract:This study aimed to explore the mechanisms through which salvianolic acid B (Sal-B) exerts its effects during myocardial ischemia-reperfusion injury (MI/RI), aiming to demonstrate the potential pharmacological characteristics of Sal-B in the management of coronary heart disease. First, Sal-B-related targets and MI/RI-related genes were compiled from public databases. Subsequent functional enrichment analyses using the protein–protein interaction (PPI) network, gene ontology (GO), and the Kyoto Encyclopedia of Genes and Genomes (KEGG) predicted the core targets and approaches by which Sal-B counters MI/RI. Second, a Sal-B-treated MI/RI mouse model and oxygen–glucose deprivation/reoxygenation (OGD/R) H9C2 cell model were selected to verify the main targets of the network pharmacological prediction. An intersectional analysis between Sal-B and MI/RI targets identified 69 common targets, with a PPI network analysis highlighting caspase-3, c-Jun N-terminal kinase (JNK), and p38 mitogen-activated protein kinase (p38) as central targets. GO and KEGG enrichment analyses indicated remarkable enrichment of the apoptosis pathway among these targets, suggesting their utility in experimental studies in vivo. Experimental results demonstrated that Sal-B treatment not only mitigated myocardial infarction size following MI/RI injury in mice but also modulated the expression of key apoptotic regulators, including Bcl-2-Associated X (Bax), caspase-3, JNK, and p38, alongside enhancing the B-cell lymphoma-2 (Bcl-2) expression, thereby inhibiting myocardial tissue apoptosis. This study leveraged an integrative network pharmacology approach to predict Sal-B's potential targets in MI/RI treatment and verified the involvement of key target proteins within the predicted signaling pathways through both in vivo and in vitro experiments, offering a comprehensive insight into Sal-B's pharmacological mechanism in MI/RI management.

pharmacology & pharmacy,chemistry, medicinal

What problem does this paper attempt to address?

The problem this paper attempts to address is to explore the mechanism of action of Salvianolic acid B (Sal-B) in Myocardial Ischemia-Reperfusion Injury (MI/RI) and to verify its potential pharmacological properties, with the aim of providing new insights for the clinical treatment of coronary heart disease.

Specifically:
1. **Network Pharmacology Analysis**: By screening databases and Swiss Target Prediction, the relevant targets of Sal-B were identified and cross-analyzed with MI/RI-related genes, ultimately identifying 69 potential MI/RI targets.
2. **Experimental Validation**: By constructing a mouse model of myocardial ischemia-reperfusion and an oxygen-glucose deprivation/reoxygenation (OGD/R) model of H9C2 cells, the effects of these targets were validated. The study found that Sal-B significantly reduced the area of myocardial infarction and regulated the expression of key apoptosis regulatory factors such as Bcl-2, Bax, and caspase-3, thereby inhibiting apoptosis in myocardial tissue.
3. **Signal Pathway Analysis**: KEGG pathway enrichment analysis indicated that Sal-B mainly exerts its effects by influencing signal pathways related to apoptosis, inflammatory response, and oxidative stress response, especially the MAPK signaling pathway.

In summary, this paper aims to reveal the specific mechanisms of Sal-B in myocardial ischemia-reperfusion injury through network pharmacology methods and experimental validation, providing a theoretical basis for the further development of new drugs targeting coronary heart disease.